Last update 15 Nov 2024
Bevacizumab biosimilar (Chia-tai Tianqing)
Last update 15 Nov 2024
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms TQ-B2302, TQB2302 |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 41632H
The sequence is quoted from: *****
Sequence Code 41637L
The sequence is quoted from: *****
Related
5
Clinical Trials associated with Bevacizumab biosimilar (Chia-tai Tianqing)贝伐珠单抗注射液（4ml：100mg）在健康男性受试者中随机、双盲、单剂量、平行设计的药代动力学和安全性的相似性临床研究。
[Translation] A randomized, double-blind, single-dose, parallel-design similarity clinical study on the pharmacokinetics and safety of bevacizumab injection (4ml: 100mg) in healthy male subjects.
比较TQ-B2302与安维汀@联合紫杉醇/卡铂治疗非鳞状非小细胞肺癌有效性和安全性的III期临床研究
[Translation] Phase III clinical study comparing the efficacy and safety of TQ-B2302 and Avastin@ combined with paclitaxel/carboplatin in the treatment of non-squamous non-small cell lung cancer
随机、双盲、单剂量、平行比较贝伐珠单抗注射液与Avastin在健康男性志愿者中药代动力学和安全性研究
[Translation] A randomized, double-blind, single-dose, parallel comparison of the pharmacokinetics and safety of bevacizumab injection and Avastin in healthy male volunteers
100 Clinical Results associated with Bevacizumab biosimilar (Chia-tai Tianqing)
Login to view more data
100 Translational Medicine associated with Bevacizumab biosimilar (Chia-tai Tianqing)
Login to view more data
100 Patents (Medical) associated with Bevacizumab biosimilar (Chia-tai Tianqing)
Login to view more data
100 Deals associated with Bevacizumab biosimilar (Chia-tai Tianqing)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Metastatic Colorectal Carcinoma | CN | 28 Feb 2023 | |
| Metastatic Colorectal Carcinoma | CN | 28 Feb 2023 | |
| Non-squamous non-small cell lung cancer | CN | 28 Feb 2023 | |
| Non-squamous non-small cell lung cancer | CN | 28 Feb 2023 | |
| Recurrent Glioblastoma | CN | 28 Feb 2023 | |
| Recurrent Glioblastoma | CN | 28 Feb 2023 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Ovarian Cancer | Phase 1 | CN | 30 Mar 2017 | |
| Uterine Cervical Cancer | Phase 1 | CN | 30 Mar 2017 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | - | 98 | (A single-dose bevacizumab biosimilar) | vkpikoakqs(ystanxcwsm): GMRs = 96.27 View more | Positive | 12 Aug 2022 | |
(Bevacizumab was given per cycle) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free